Document:

Exhibit 10.12

 

JOHN
E. HERZOG

824
HARBOR ROAD

SOUTHPORT,
CT 06890

 

December
10, 2019

 

Re:
The OLB Group Financial Support

 

As
a significant shareholder of The OLB Group, Inc. (the “Company”), I have reviewed the Company's financial projections,
current financial position, debt arrangements and other financial obligations for the upcoming twelve months. I have also reviewed
the Company’s registration statement in connection with a potential public offering of the Company’s common stock
and warrants (the “Offering”).

 

On
November 15, 2018, I confirmed a commitment and ability to continue to support the Company by providing financial assistance to
enable the Company to continue its business operations as a going concern for at least the following twelve months. In May 2019,
I agreed to extend the commitment until November 30, 2020. In November 2019, I clarified such commitment whereby I would provide
support for working capital needs, other than capital required to satisfy the obligations of the Company with respect to the Loan
and Security Agreement, dated as of November 2, 2016, by and among GACP, the lenders thereunder and the Debtors, and related loan
documents, as amended (the “Excel Loan”).

 

Accordingly,
I hereby confirm my commitment and ability to continue to support the Company’s working capital needs (other than obligations
of the Company to pay principal or interest with respect to the Excel Loan) by providing adequate financial assistance to enable
the Company to continue its business operations as a going concern until the earlier of (a) the closing of the Offering (the “Closing”)
and (b) November 30, 2020. I further covenant and agree to negotiate in good faith with the Company regarding the repayment of
any financial assistance that I provide to the Company in connection with my commitment.

 

	 	Sincerely,
	 	 
	 	/s/
    John E. Herzog
	 	John E. HerzogExhibit 10.1

 

SUBLICENSE AGREEMENT

 

*
Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[****]”)
because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

 

This
SUBLICENSE AGREEMENT (the “Agreement”) is made and signed as of June 27, 2018 (the “Effective
Date”) by and between MABVAX THERAPEUTICS HOLDINGS, INC., with a principal place of business at 11535 Sorrento
Valley Road, Suite 400, San Diego, CA 92121 (“MabVax”), on the one hand, and Y-MABS THERAPEUTICS INC.,
with a principal place of business at 230 Park Avenue, Suite 3350, New York, NY 10169 (“YmAbs”), on the other
hand. MabVax and YmAbs are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS,
MabVax and Sloan-Kettering Institute for Cancer Research, (“SKI”) have entered into that certain Exclusive License
Agreement dated June 30, 2008 and amended on May 11, 2011 (and subject to the side letter agreement of even date hereof (the “Side
Letter”) of MabVax and SKI), under which SKI granted MabVax an exclusive license under SKI’s rights in the invention
that is the subject of the disclosure entitled “Polyvalent Conjugate Vaccines for Cancer (SK#14491),” and patent rights
thereon (the “SKI License Agreement”);

 

WHEREAS,
MabVax desires to grant to YmAbs, and YmAbs desires to obtain, a sublicense under MabVax’s interest and rights in, to, and
under such patent rights for use in developing and commercializing a vaccine against neuroblastoma; and

 

WHEREAS,
SKI and MabVax have agreed to amend certain terms of the SKI License Agreement with respect to, among other things, the obligations
hereby assumed by YmAbs or its sublicensees in accordance with the Side Letter of MabVax and SKI.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the foregoing and the covenants and promises contained
in this Agreement and intending to be legally bound, the Parties agree as follows:

 

 

 

ARTICLE 1. DEFINITIONS

 

The terms, as defined herein, shall
have the same meanings in both their singular and plural forms:

 

		1.1	“Affiliate” means a corporation, partnership,
trust or other entity that directly, or indirectly through one or more intermediates, controls, is controlled by or is under common
control with a specified Party but only for so long as such relationship exists. For such purposes, “control”, “controlled
by”, and “under common control with” shall mean the possession of the power to direct or cause the direction
of the management and policies of an entity, whether through the ownership of voting equity, voting member or partnership interests,
control of a majority of the board of directors or other similar body, by contract, or otherwise, including without limitation,
in the case of a corporation, the direct or indirect ownership of fifty percent (50%) or more of its outstanding voting shares.

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

  

     

     

    

 

		1.2	“Control” means, with respect to items,
information, or intellectual property rights (including patents, patent applications and/or know-how), possession by a Party of
the power and authority, whether arising by ownership, license, or other authorization, to grant and authorize the licenses or
sublicenses, as applicable, under such items, information, or intellectual property rights (including patents, patent applications
and/or know-how) of the scope granted to the other Party in this Agreement.

 

		1.3	“FDA” means the United States Food
and Drug Administration.

 

		1.4	“Field” means the prevention or treatment
of neuroblastoma by means of administering a bi-valent ganglioside vaccine.

 

		1.5	“Know-How” means ideas, inventions,
discoveries, trade secrets, know how, improvements, data, and information (which as of the Effective Date are not subject to a
patent or patent application), together with all experience, data, formulas, procedures, and results, and improvements thereon,
that (a) exist as of the Effective Date, (b) are under the Control of MabVax, and (c) are listed on Exhibit B.

 

		1.6	“Licensed Process” means any process
which either (a) is covered in whole or in part by the Patent Rights, (b) would infringe a Valid Claim but for this Agreement,
or (c) uses Know-How, in each case, in any country in which such process is practiced.

 

		1.7	“Licensed Product” means any product
or part thereof which: (a) either (i) is covered in whole or in part by the Patent Rights; (ii) would infringe a Valid Claim but
for this Agreement; or (iii) uses Know-How, in each case, in the country in which any product or part thereof is made, leased,
used or sold; or (b) is manufactured using a Licensed Process.

 

		1.8	“Net Income” means [****].

 

		1.9	“Patent Rights” means: (a) the United
States and foreign patents and patent applications listed in Exhibit A which is a subset of the patents and patent applications
licensed to MabVax in the SKI License Agreement; (b) United States and foreign patents issued from the applications listed in
Exhibit A, and from divisionals and continuations of these applications; (c) claims of U.S. and foreign continuation-in-part applications,
and of the resulting patents, which are directed to subject matter specifically described in or entitled to or claim priority
on the U.S. and foreign patent applications listed in Exhibit A; and (d) any reissues, extensions, substitutions, re-examinations,
supplementary protection certificates, and patents of addition of patents and patent applications described in (a), (b), or (c)
above.

  

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	2	 

     

    

 

		1.10	“Priority Review Voucher” means a
voucher issued to YmAbs under the United States Congress Rare Pediatric Disease Priority Review Voucher Program, effectuated by
the

 

		 	FDA under Section 529 to the Federal Food, Drug, and
Cosmetic Act as part of a rare pediatric disease product application made by YmAbs for a Licensed Product only.

 

		1.11	“Territory” means worldwide.

 

		1.12	“Valid Claim” means any claim of an
issued and unexpired patent within the Patent Rights that has not been held unenforceable, unpatentable or invalid by a decision
of a court or governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time allowed
for appeal.

 

ARTICLE 2. GRANT

 

2.1          Sublicense. Subject to the terms and conditions of this Agreement and the SKI License Agreement, MabVax hereby grants
to YmAbs under all rights granted to it under the SKI License Agreement including the Patent Rights and Know-How, an exclusive
(even to MabVax), worldwide sublicense, including the right to grant sublicenses, to develop, make, have made, use, sell, offer
to sell, import, and export Licensed Products in the Field in the Territory and to use the Know-How in connection therewith. For
clarity, the Parties intend that YmAbs shall have the right to practice all rights granted to MabVax under the SKI License Agreement
to the extent applicable to the exploitation of the Licensed Products in the Field in the Territory.

 

2.2          The SKI License Agreement. YmAbs acknowledges that the rights granted to YmAbs under this Agreement that constitute
a sublicense under the SKI License Agreement are, in addition to being limited by and are subject to the terms and conditions of
this Agreement, further limited by the terms and conditions of the SKI License Agreement. Notwithstanding Article 8, pursuant to
the SKI License Agreement, YmAbs acknowledges that MabVax will furnish to SKI a true and complete copy of this Agreement and any
current and future amendments thereto.

 

2.3           Incorporation by Reference. MabVax and YmAbs hereby agree that the SKI License Agreement is incorporated into this Agreement
by reference and made a part hereof, and the terms and conditions of the SKI License Agreement shall govern the sublicense from
MabVax to YmAbs pursuant to Section 2.1, provided however that it is understood and agreed that YmAbs’ obligations resulting
from such incorporation of the SKI License Agreement shall never exceed those described in Section 3.4 below (for clarity, such
incorporation does not limit payment obligations owed by YmAbs to MabVax directly). Nothing in this Agreement shall be deemed to
grant to YmAbs any rights under the rights sublicensed to it under the SKI License Agreement beyond those MabVax has the right
to grant to YmAbs pursuant to the SKI License Agreement.

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	3	 

     

    

 

2.4          Transfer of Know-How. Within thirty (30) days after the Effective Date, MabVax shall deliver to YmAbs the materials
and information set forth in Exhibit B. The Parties acknowledge and agree that YmAbs will obtain directly from SKI additional information
and know-how relating to an investigator-sponsored clinical trial of Licensed Products in the Field conducted by SKI, and that
such information and know-how is not included in the Know-How.

 

2.5          Transfer of Vaccine. Any and all supply of the neuroblastoma vaccine owned by MabVax as of the Effective Date shall
be transferred to YmAbs within fifteen (15) days after the Effective Date at no charge to YmAbs.

 

ARTICLE 3. CONSIDERATION & DILIGENCE
OBLIGATIONS

 

3.1          Upfront Payment. In partial consideration for the rights granted to YmAbs under this Agreement, YmAbs shall pay to MabVax
a one-time, non-refundable payment of seven hundred thousand U.S. dollars ($700,000) within five (5) days after YmAbs’ receipt
of the Know-How pursuant to Section 2.4.

 

3.2          Continuation Payment. In partial consideration for the rights granted to YmAbs under this Agreement, YmAbs shall pay
to MabVax a one-time, non-refundable payment of six hundred thousand U.S. dollars ($600,000) within five (5) days after the first
anniversary of the Effective Date, provided that no notice of termination of this Agreement has been made by YmAbs before such
date.

 

		3.3	Priority Review
                                         Voucher Revenue Share.

 

		(a)	In partial consideration for the rights granted to YmAbs under this Agreement, YmAbs shall
                                                                               pay MabVax a one-time amount equal to  twenty percent (20%) of Net Income for the sale by YmAbs of one Priority Review
                                                                               Voucher.

 

		(b)	YmAbs will use commercially reasonable efforts to obtain
the Priority Review Voucher set forth in Section 3.3(a) and thereafter to sell such Priority Review Voucher.

 

3.4          Assumed Obligations. In consideration for the rights granted to YmAbs under this Agreement, YmAbs agrees that it shall
solely be responsible for the amounts payable by MabVax to SKI and the other obligations of MabVax to SKI pursuant to the SKI License
Agreement to the extent incurred after the Effective Date and solely (i) arising out of YmAbs’ exercise of its sublicense
under the SKI License Agreement and (ii) to the extent applicable to Licensed Products in the Field, including without limitation
those that are set forth in Exhibit C (the “Assumed Obligations”). Such payments shall be made in accordance
with Sections 5.5 and 5.6 of the SKI License Agreement, applied mutatis mutandis as if such payments were payable by MabVax
to SKI. YmAbs confirms that it has received a copy of and reviewed a copy of the SKI License Agreement, and covenants that it shall
perform all obligations of MabVax to the extent incurred after the Effective Date and solely (i) arising out of YmAbs’ exercise
of its sublicense under the SKI License Agreement and (ii) to the extent applicable to Licensed Products in the Field.

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	4	 

     

    

 

3.5          Clarification.
For clarity, no development milestones or royalties are payable by YmAbs to MabVax under this Agreement in consideration for
the rights granted by MabVax under this Agreement. Any payments payable by MabVax to SKI under the SKI License Agreement arising
as a result of payments made by YmAbs to MabVax under this Agreement shall be of no concern to YmAbs. For clarity, this Section
3.5 does not supersede the Assumed Obligations in Section 3.4. Further, for clarity it is noted that YmAbs shall not assume any
obligations of MabVax to make payments to SKI under clause 4 of the Side Letter.

 

		3.6	Diligence Milestones. YmAbs agrees to use [****] to:

 

		(a)	[****] within [****] from the Effective Date of this Agreement;

		(b)	[****] within [****] from the Effective Date of this
Agreement; and

		(c)	make
(or have made) the [****] within [****] from the Effective Date of this Agreement.

 

ARTICLE 4. RECORDS

 

4.1          Records. YmAbs
will keep, and cause its Affiliates and sublicensees to keep, full, complete and proper records and accounts of the sales of Priority
Review Vouchers in sufficient detail to enable the payment set forth in Section 3.3(a) to be determined.

 

ARTICLE 5. INTELLECTUAL
PROPERTY

 

5.1          Prosecution. As of the Effective Date, [****] is responsible for the prosecution and maintenance of the Patent Rights
under the supervision of [****] [****].

 

5.2          Cooperation. [****] shall fully cooperate with and assist [****] in performing activities reasonably required for filing
and prosecuting patent, trademark and copyright applications and otherwise protecting [****] rights to any of the Know-How.
In this regard, [****] shall execute such filings, assignments and other documents as [****] deems necessary. [****] will reimburse
[****] for all reasonable costs and expenses incurred in performing [****] obligations under this Section 5.2.

  

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	5	 

     

    

 

		5.3	Enforcement.

 

		(a)	[****] shall have the first right (but not the obligation)
to institute, prosecute, and control any action or proceeding with respect to any infringement of Patent Rights, at [****]’
expense and by counsel of its own choice, in [****] own name and under [****] direction and control, including the
right to control the defense of any challenges to such Patent Rights as a counterclaim in such infringement proceeding as well
as the defense of declaratory judgment actions. [****] shall cooperate in the institution and prosecution of such infringement
suit, including without limitation consenting to being joined in such infringement suit as a party plaintiff.

 

		(b)	If [****] determines not to institute an action or proceeding with respect to a given
                                                                               infringement of Patent Rights, it shall notify and consult with [****] of such decision, and [****] shall thereupon have the
                                                                               right (but not the obligation) to institute an action or proceeding with respect to such infringement, at [****] expense with
                                                                               counsel of its choice, [****]. If [****]does not institute such action or proceeding [****], then [****] shall thereupon have
                                                                               the                                                                                right (but not the obligation) to
                                                                               institute such action or proceeding, at [****] expense with counsel of its choice. If either
                                                                               [****] or [****] determines to undertake such action or proceeding, [****] any such action or proceeding as a party at [****] or
                                                                               [****],                                                                                as applicable, if doing so is necessary for
                                                                               the purposes of establishing standing.

 

		(c)	[****].

 

5.4          SKI License Agreement. Notwithstanding the foregoing provisions of this Section 5, the provisions of the SKI License
Agreement shall control with respect to intellectual property rights and responsibilities should they conflict with this Section
5.

 

ARTICLE 6. TERM AND TERMINATION

 

6.1          Term. The term of this Agreement shall commence on the Effective Date and, unless this Agreement is earlier terminated
in accordance with the provisions herein, shall subject to Section 6.4 below end on the expiration or termination date of the SKI
License Agreement.

 

6.2          Termination for Material Breach. If either
Party commits a material breach of this Agreement, then the other Party may give the breaching Party written notice of default
and intent to terminate. The non-breaching Party shall be entitled to terminate this Agreement if the breaching Party fails to
cure the default within sixty (60) days of receiving such written notice.

 

6.3          Termination
at Will. YmAbs shall have the right to terminate this Agreement at will upon [****] advance written notice to MabVax.

 

6.4          Termination of SKI License Agreement. This Agreement shall terminate upon the expiration or termination of the SKI License
Agreement, provided that if YmAbs is in material compliance with this Agreement as of such termination date, then this Agreement
shall be assumed by SKI on the terms negotiated hereunder as provided in Section 14.5 of the SKI License Agreement, provided that
SKI shall not be liable to YmAbs with respect to any obligations of MabVax to YmAbs that exceed the obligations of SKI to MabVax
under the SKI License Agreement.

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	6	 

     

    

 

		6.5	Effect of Termination
                                         or Expiration.

 

(a)           All rights and licenses granted to YmAbs under this Agreement shall terminate upon termination of this Agreement. [****]. Termination shall not relieve
YmAbs of its obligations to pay any fees owed at the time of termination and shall not impair any accrued right of MabVax. Termination
shall not relieve YmAbs of any obligation or liability accrued under this Agreement prior to termination, or rescind any payment
made to MabVax or action by YmAbs prior to the time termination becomes effective.

 

(b)           YmAbs will redeliver and assign to MabVax all Know-how and regulatory filings and approvals for Licensed Products then owned
by YmAbs or its Affiliates or sublicensees, [****]. In this regard, YmAbs shall execute such filings, assignments and other documents as is necessary for such
purpose.

 

		(c)	The following Articles shall survive the termination
or expiration of this Agreement:

 

		(i)	Article 4 (RECORDS);

 

		(ii)	Article 7 (REPRESENTATIONS AND WARRANTIES; LIMITATION
OF LIABILITY; INDEMNIFICATION);

 

		(iii)	Article 8 (CONFIDENTIALITY); and

 

		(iv)	Article 9 (MISCELLANEOUS PROVISIONS).

 

ARTICLE 7. REPRESENTATIONS
AND WARRANTIES; LIMITATION OF LIABILITY; INDEMNIFICATION

 

		7.1	Representations and Warranties.

 

		(a)	MabVax hereby represents and warrants to YmAbs that:

 

(i)              
It is duly organized and validly existing under the laws of its jurisdiction of organization and has the requisite power
and authority to execute, deliver and perform its obligations under this Agreement.

 

(ii)             
MabVax has not granted as of the Effective Date, and shall not grant during the Term, any right, option, license or interest
in or to any of the Patent Rights that is in conflict with the rights and licenses granted to YmAbs under this Agreement.

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	7	 

     

    

 

(iii)           
As of the Effective Date, to MabVax’s knowledge, MabVax is not in possession of information that would, in its reasonable
opinion and to its knowledge, render invalid and/or unenforceable any claims that are in any of the Patent Rights, and MabVax has
no knowledge of any infringement of any of the Patent Rights by any third party.

 

(iv)           
As of the Effective Date, MabVax is not currently bound by any agreement with any third party, or by any outstanding order,
judgment, or decree of any court or administrative agency, that restricts it from granting to YmAbs the rights and licenses as
set forth in this Agreement.

 

(v)            
MabVax has until now and will continue to comply with all of its obligations to SKI under the terms of the SKI License Agreement
in all material respects and will not take any action to terminate the SKI License Agreement without the prior written consent
of YmAbs. Further, MabVax will not amend any of the terms of the SKI License Agreement that affect the rights and/or obligations
of YmAbs, unless with the prior written approval of YmAbs, provided that such prior written approval of YmAbs shall not be needed
for amendment of applicable provisions of the SKI License Agreement relating to payment obligations that do not affect YmAbs’
obligations.

 

(vi)           
Exhibit A contains a complete and accurate list of all patents included in the Patent Rights that claim or Cover the Licensed
Products or Licensed Process. Except for the Patent Rights, MabVax does not own or Control (by license or otherwise), as of the
Effective Date, any patent that covers any invention that is necessary or useful to develop, manufacture, or commercialize any
Licensed Product in the Field in the Territory.

 

		(b)	YmAbs hereby represents and warrants to MabVax that:

 

(i)             
It is duly organized and validly existing under the laws of its jurisdiction and has the requisite power and authority to
execute, deliver and perform its obligations under this Agreement.

 

(ii)            
YmAbs will use commercially reasonable efforts to obtain and seek to sell any resulting Priority Review Voucher as set forth
in Section 3.3.

 

(iii)           
For the term of this Agreement, upon the commencement
of clinical use, production, sale, or transfer by YmAbs, whichever occurs first, of any Licensed Product, YmAbs shall obtain and
carry in full force and effect general liability insurance which shall protect YmAbs and MabVax in regard to events covered by
Section 7.5(b). Such insurance shall be written by a reputable insurance company, shall list SKI as an additional named insured
thereunder, shall be endorsed to include liability coverage, and shall require thirty (30) days written notice to be given to MabVax
prior to any cancellation or material change thereof that would violate the foregoing. The limits of such insurance shall not be
less than $[****] per occurrence with an annual aggregate of
$[****] for personal injury, death or property damage. YmAbs shall provide MabVax with Certificates of Insurance evidencing the
same.

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	8	 

     

    

 

7.2         
DISCLAIMER OF WARRANTY. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDES ANY WARRANTIES, WHETHER
WRITTEN OR ORAL, EXPRESS OR IMPLIED, REGARDING THE LICENSED PRODUCTS USED IN CLINICAL TRIALS OR FOR COMMERCIAL USE, AND EACH PARTY
HEREBY DISCLAIMS ALL OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND FREEDOM FROM INFRINGEMENT OF THIRD PARTY RIGHTS.

 

7.3         
LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE
OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS
OF BUSINESS, OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE
HEREUNDER, EXCEPT WITH RESPECT TO ANY BREACH OF THE CONFIDENTIALITY OBLIGATIONS OF ARTICLE 8 OR TO THE EXTENT THAT THE LOSS IS
COVERED BY THE INDEMNIFICATION OBLIGATIONS OF A PARTY UNDER SECTION 7.5. EXCEPT FOR MABVAX’S GROSS NEGLIGENCE OR BREACH OF
ANY OF ITS REPRESENTATIONS OR WARRANTIES HEREUNDER, MABVAX SHALL NOT BE LIABLE TO YMABS FOR ANY DAMAGES UNDER THIS AGREEMENT EXCEEDING
THE AMOUNTS PAID TO MABVAX UNDER THIS AGREEMENT.

 

7.4        
MabVax shall have no responsibility for the quality of the Know-How and other items delivered to YmAbs. YmAbs agrees
that the delivered Know-How and other items are delivered “As Is,” “With All Faults,” and “With All
Defects.” YmAbs is solely responsible for determining whether the delivered Know-How and other items have applicability or
utility in YmAbs’ contemplated exploitation of Licensed Products and in the Field, with no further assurances, and YmAbs
assumes all risk and liability in connection with such determination.

 

		7.5	Indemnification.

 

(a)              
MabVax hereby agrees to indemnify, defend and hold harmless YmAbs from and against any and all costs, expenses, judgments,
liabilities, damages and losses of any type (including reasonable attorney fees and costs) that YmAbs may suffer as a result of [****], except to the extent arising from an action for
which YmAbs must indemnify MabVax pursuant to subsection (b).

 

(b)              
YmAbs hereby agrees to indemnify, defend and hold harmless MabVax from and against any and all costs, expenses, judgments,
liabilities, damages and losses of any type (including reasonable attorney fees and costs) that MabVax may suffer as a result
of [****], except
to the extent arising from an action for which MabVax must indemnify YmAbs pursuant to subsection (a).

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	9	 

     

    

 

(c)              
In the event that either Party seeks indemnification under the terms of this Section 7.5(a or b), it shall inform the other
Party of the claim as soon as reasonably practicable after it receives notice thereof, shall permit the indemnifying Party, at
indemnifying Party’s cost, to assume direction and control of the defence of the claim, and shall co-operate as requested
(at the expense of the indemnifying Party), in the defense of the claim. An indemnifying Party shall not settle or otherwise compromise
any claim or suit in any manner that adversely affects the other Party hereunder or imposes obligations on the other Party in addition
to those set forth in this Agreement, without prior written consent of the indemnified Party, for which consent shall not be unreasonably
withheld or delayed.

 

(d)               YmAbs hereby agrees to indemnify, defend and hold harmless [****], and their respective successors, heirs and assigns (each an “Indemnitee”), from
and against any and all costs, expenses, judgments, liabilities, damages and losses of any type (including reasonable
attorney fees and costs) that they may suffer as a result of [****]. In the event that an Indemnitee seeks indemnification under the terms of
this Section 7.5 (d) it shall inform YmAbs of the claim as soon as reasonably practicable after it receives notice thereof,
shall permit YmAbs, at YmAbs’ cost, to assume direction and control of the defence of the claim, and shall co-operate
as requested (at the expense of YmAbs), in the defence of the claim. YmAbs shall not settle or otherwise compromise any claim
or suit in any manner (i) that does not release the Indemnitee from all liability with respect to such third party claims; or
(ii) that adversely affects [****], without prior written consent of [****], for which consent shall not be
unreasonably withheld or delayed.

 

ARTICLE 8. CONFIDENTIALITY

 

8.1          Each
of the Parties undertakes to treat as strictly confidential all information that it receives from the other Party relating to
its business affairs (“Confidential Information”). Each of the Parties may disclose the other Party’s
Confidential Information to its employees, directors, agents, affiliates, or third party contractors, potential or actual investors,
acquirers or collaborators, and advisors (“Representatives”); provided that such Representatives have a need
to know the Confidential Information in order to carry out this Agreement and are under a written obligation to
safeguard the Confidential Information prior to disclosure. This duty of confidentiality shall not include Confidential Information
that is already in the public domain, which enters the public domain for reasons beyond the relevant Party’s control, or
which must be disclosed under a statutory obligation (provide the disclosing Party uses reasonable efforts to seek confidential
treatment thereof where available). This duty of confidentiality shall survive any expiration or termination of this Agreement
for [****].

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	10	 

     

    

 

8.2          Neither Party shall disclose the terms and conditions of this Agreement or activities under this Agreement except as
may be required by law or rules of a securities exchange. Notwithstanding the foregoing, with respect to complying with the disclosure
requirements of any governmental authority or securities exchange in connection with any required filing of this Agreement, the
Parties shall consult with one another concerning which terms of this Agreement shall be requested to be redacted in any public
disclosure of the Agreement, and in any event each Party shall seek reasonable confidential treatment for any public disclosure
by any such governmental authority or securities exchange. Each Party shall have the right to issue press releases in regards to
this Agreement with the prior written agreement of the other Party or as required to comply with any law or by the rules of any
stock exchange or automated quotation system (in the case of such required disclosure, by providing five (5) days’ notice
to the other Party and reasonably considering comments provided by such other Party within two (2) days after such notice, or such
shorter notice and comment time periods as the disclosing Party may reasonably require).

 

ARTICLE 9. MISCELLANEOUS PROVISIONS

 

9.1          Relationship of the Parties. The Parties are independent contractors and nothing herein shall be construed as creating
a partnership, joint venture, employment or the relationship of principal and agent between the parties.

 

9.2          Assignment. This
Agreement may not be assigned, in whole or in part, by a Party without the prior written consent of the other Party, except
that such prior consent shall not be needed for assignment of this Agreement to a Party’s affiliate or
successor-in-interest (whether by merger, acquisition, asset purchase, share purchase, or other transaction). Subject to the
first sentence of this Section 9.2, this Agreement will be binding upon, inure to the benefit of and be enforceable by, the
Parties’ successors and permitted assigns.

 

9.3          Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

9.4          Force Majeure.  Neither Party shall be liable or responsible to the other Party for loss or damages, nor shall it have
any right to terminate this Agreement for any default or delay attributable to any event beyond its reasonable control and without
its fault or negligence, including without limitation acts of God, acts of government (including injunctions), fire, flood, earthquake,
strike, lockout, labor dispute, breakdown of plant, shortage of critical equipment, loss or unavailability of manufacturing facilities
or material, casualty or accident, civil commotion, acts of public enemies, acts of terrorism or threat of terrorist acts, blockage
or embargo and the like;

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	11	 

     

    

 

provided, however, that in each
such case the Party affected shall (i) use reasonable efforts to avoid such occurrence and to remedy it promptly and (ii) give
prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations
hereunder as it is thereby disabled from performing for so long as it is so disabled and for thirty (30) days thereafter, and
the Party receiving notice shall be similarly excused from its respective obligations which it is thereby disabled from performing;
provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such
cause. Notwithstanding the foregoing, nothing in this Section 9.4 shall excuse or suspend the obligation to make any payment due
hereunder in the manner and at the time provided.

 

9.5             
Notices. All notices and other communications hereunder shall be in writing and shall be deemed given (a) if delivered
personally or by facsimile transmission (receipt verified), (b) three (3) business days after mailed by registered or certified
mail (return receipt requested), postage prepaid, or (c) one (1) business day after sent by express courier service, to the Parties
at the following addresses (or at such other address for a Party as shall be specified by like notice, provided that notices of
a change of address shall be effective only upon receipt thereof):

 

	If to YmAbs:	YmAbs Therapeutics Inc.,

230 Park Avenue, Suite 3350

New York, NY 10169
	 	USA
	 	Att: Thomas Gad, President

Telephone: [****]
	 	E-mail: [****]
	 	 
	With copies to:	Y-mAbs Therapeutics Inc.
	 	230 Park Avenue, Suite 3350 

New York, N.Y. 10169
	 	Attn.: Sune R. Nyland, Esq. 

Telephone: [****]

E-mail: [****]
	 	 
	If to MabVax:	MabVax Therapeutics Holdings, Inc.
	 	11535 Sorrento Valley Road, Suite 400

San Diego, CA 92121
	 	USA
	 	
        Att: David Hansen, President and CEO

Telephone: 858.259.9405 x 301 

        Mobile: [****]

        E-mail: [****]

 

9.6          Governing
Law; Jurisdiction. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the
State of New York, U.S.A., without regard to its or any other jurisdiction’s choice of law rules. The Parties hereto
submit and consent to the jurisdiction of the courts of the State of New York, including the federal courts located therein, should federal jurisdiction
requirements exist, in any action brought to enforce (or otherwise relating to) this Agreement.

  

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	12	 

     

    

 

9.7          Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless
made in writing and signed by a duly authorized officer of each Party.

 

9.8          Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving
Party. A waiver by either Party of any term or condition of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for any similar instance in the future or any subsequent breach hereof.

 

9.9          Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable laws, but if any provision of this Agreement is held to be prohibited by or invalid under applicable
laws, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder
of this Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that
preserves the original purpose of this Agreement.

 

9.10        Construction. The descriptive headings of this Agreement are for convenienceonly, and shall be of no force or effect
in construing or interpreting any of the provisions of this Agreement. Except where the context otherwise requires, wherever used
the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders. The language
of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be
applied against either Party hereto.

 

9.11        Entire Agreement; Third Party Beneficiaries. This Agreement constitutes and contains the complete, final and exclusive
understanding and agreement of the Parties, and cancels and supersedes any and all prior or contemporaneous negotiations, correspondence,
understandings, and agreements, whether oral or written, between the Parties respecting the subject matter hereof. This Agreement
is not intended to confer upon any person other than the Parties hereto, as applicable, any rights or remedies.

 

9.12        Counterparts; Electronic Delivery. This Agreement may be executed simultaneously in two counterparts, either one of
which need not contain the signature of more than one Party, but both of which taken together shall constitute one and the same
agreement. Signatures to this Agreement transmitted by facsimile, by email in “portable document format” or “.pdf”,
or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement, shall have
the same effect as physical delivery of the paper document bearing original signature.

 

[Signature Page Follows]

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

    	 	13	 

     

    

  

IN WITNESS
WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date
by their duly authorized representatives as set forth below:

 

 

	Y-MABS THERAPEUTICS, INC.	 	MABVAX THERAPEUTICS HOLDINGS, INC.
	 	 	 
	 	 	 
	By:	/s/ Thomas Gad	 	By:	/s/ J. David Hansen
	 	 	 	 	 
	Name: 	Thomas Gad	 	Name:	J. David Hansen
	 	 	 	 	 
	Title: 	Chairman, President	 	Title:	President and CEO

  

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

 

Exhibit A

 

Patent Rights

 

[****]

  

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

 

Exhibit B

 

Know-How

 

[****]

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

 

     

     

    

 

Exhibit C

 

Assumed Obligations

 

Assumed obligations means all
due diligence obligations under Article III, payment obligations under Article V, reporting obligations under Article VI, and obligations
to SKI under Articles IX, XI, XII, XIII and XIV of the SKI License Agreement, all solely with respect to the Licensed Products
in the Field and incurred after the Effective Date (as they may have been amended or waived with respect to YmAbs or its sublicensees
under the Side Letter of even date between MabVax and SKI).

 

YmAbs agrees that it is solely
responsible for performing all obligations under the SKI License Agreement after the Effective Date that arise solely out of and
relate solely to YmAbs’ development, manufacture, use or commercialization of Licensed Products in the Field, and that it
will comply with all such terms of the SKI License Agreement in a timely manner as required thereunder (all as they may have been
amended or waived with respect to YmAbs or its sublicensees under the Side Letter of even date between MabVax and SKI).

 

 

[****] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]